therapeutics

Development of treatments for sarcopenia: new challenges, opportunities and perspectives.

Sarcopenia is characterized by loss of muscle mass, strength and function, and is associated with decline in physical function, falls, fractures and premature mortality. Despite increasing recognition of its clinical and societal burden, progress in translating advances in sarcopenia research...

🗓️ 2026-11-17
📰 Publication: Nature Reviews Rheumatology
Read MoreDevelopment of treatments for sarcopenia: new challenges, opportunities and perspectives.

ZIF-8-Based Nanodelivery of Tectorigenin for Alleviating Skeletal Muscle Atrophy via Inhibition of Oxidative Stress and Inflammation.

BACKGROUND

Skeletal muscle atrophy is a pathological condition characterized by a progressive loss of muscle mass and function. Its core mechanisms involve an imbalance between protein synthesis and degradation, caused by oxidative stress and inflammation. Tectorigenin (TG) shows therapeutic potential but...

🗓️ 2026-11-10
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreZIF-8-Based Nanodelivery of Tectorigenin for Alleviating Skeletal Muscle Atrophy via Inhibition of Oxidative Stress and Inflammation.

Metabolomics Reveals Multiple Metabolic Alterations and Biomarkers of Disease Severity in Facioscapulohumeral Muscle Dystrophy.

BACKGROUND

Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is one of the most common adult-onset myopathies and is causally associated with a contraction of the D4Z4 macrosatellite repeat array on chromosome 4. It presents with a variable pattern of progressive muscle weakness...

🗓️ 2026-11-08
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreMetabolomics Reveals Multiple Metabolic Alterations and Biomarkers of Disease Severity in Facioscapulohumeral Muscle Dystrophy.

Atovaquone impedes muscle wasting in pancreatic cancer by AMPK modulation.

Cancer-induced cachexia is a multifactorial syndrome characterized by systemic inflammation and progressive skeletal muscle and fat wasting. More than 80% pancreatic cancer patients exhibit a cachectic phenotype, which significantly contributes to the overall mortality of cancer patients. Till now, there...

🗓️ 2026-11-08
📰 Publication: Cancer Letters
Read MoreAtovaquone impedes muscle wasting in pancreatic cancer by AMPK modulation.

Molecular targets for the treatment of sarcopenia: a geroscience approach.

INTRODUCTION

Sarcopenia is increasingly recognized as a multisystem geroscience condition. The limited efficacy of first-generation anabolic therapies has challenged the paradigm that increasing muscle mass is sufficient to restore physical performance, highlighting the need for therapeutic strategies that address the biological...

🗓️ 2026-11-08
📰 Publication: Expert Opinion On Therapeutic Targets
Read MoreMolecular targets for the treatment of sarcopenia: a geroscience approach.

Mitochondrial Transplantation Preserves Regenerative Capacity of Denervated Skeletal Muscle by Disrupting a Ca 2+ Overload-Mitophagy-Ferroptosis Circuit.

BACKGROUND

Denervation-induced muscle atrophy progresses during the interval between nerve injury and reinnervation, and depletion of muscle satellite cells (MuSCs) contributes to impaired functional recovery. Although mitochondrial dysfunction and impaired quality control are implicated in muscle wasting, whether excessive mitochondrial turnover...

🗓️ 2026-11-05
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreMitochondrial Transplantation Preserves Regenerative Capacity of Denervated Skeletal Muscle by Disrupting a Ca 2+ Overload-Mitophagy-Ferroptosis Circuit.

S100A9 Mediates Neuroblastoma-Associated Skeletal Muscle Atrophy via O-GlcNAcylation Repression and Activate Mitophagy Activation.

BACKGROUND

In patients with neuroblastoma (NB), skeletal muscle atrophy is a key factor linked to poor survival and decreased long-term quality of life. Nevertheless, there are still insufficient therapeutic methods that work, and the underlying mechanisms remain unclear. As persistent inflammation...

🗓️ 2026-11-05
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreS100A9 Mediates Neuroblastoma-Associated Skeletal Muscle Atrophy via O-GlcNAcylation Repression and Activate Mitophagy Activation.

Remodelling of Skeletal Muscle During Iron Deficiency Anaemia and Recovery After Intravenous Iron Therapy.

BACKGROUND

The global prevalence of iron deficiency anaemia (IDA) is about 25% and even higher in women of reproductive age and children. IDA can impair skeletal muscle by disrupting oxygen utilization, energy production and contractile function. Haematological effects of intravenous (IV)...

🗓️ 2026-11-04
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreRemodelling of Skeletal Muscle During Iron Deficiency Anaemia and Recovery After Intravenous Iron Therapy.

Circulating lipocalin-2 is associated with systemic inflammation and cachexia-related features in patients with gastrointestinal cancer.

BACKGROUND

Cancer-associated anorexia (AN) and cachexia are frequent and debilitating complications of cancer, driven by systemic inflammation and metabolic dysregulation. Lipocalin 2 (LCN2) has been implicated in immune-metabolic integration and central appetite control, however data in cancer patients are limited. This...

🗓️ 2026-11-03
📰 Publication: Frontiers In Nutrition
Read MoreCirculating lipocalin-2 is associated with systemic inflammation and cachexia-related features in patients with gastrointestinal cancer.

Baseline Physical Frailty Predicts Clinical Outcomes During Lecanemab Therapy in Early Alzheimer's Disease: A Prospective Real-World Cohort Study.

BACKGROUND

Physical frailty and sarcopenia are recognized as determinants of Alzheimer's disease (AD) progression, but their implications during anti-amyloid therapy remain unclear. We investigated their associations with longitudinal cognitive outcomes, treatment safety, tolerability, and plasma p-tau217 trajectories in patients with early...

🗓️ 2026-11-02
📰 Publication: Aging And Disease
Read MoreBaseline Physical Frailty Predicts Clinical Outcomes During Lecanemab Therapy in Early Alzheimer's Disease: A Prospective Real-World Cohort Study.

NUB1 Regulates Muscle Atrophy in Lung Cancer Cachexia via NF-κB Signaling Pathway.

Cancer-associated cachexia (CAC) is a devastating multifactorial syndrome characterized by progressive skeletal muscle atrophy. Its mechanisms remain incompletely clarified, with limited effective therapeutic targets. NUB1, a negative regulator of ubiquitin-like proteins mediating protein degradation, has not been fully elucidated in...

🗓️ 2026-11-01
Read MoreNUB1 Regulates Muscle Atrophy in Lung Cancer Cachexia via NF-κB Signaling Pathway.

Adaptive Mitochondrial Specialization in Lung Adenocarcinoma: Redox Homeostasis, Hypoxia Adaptation, and Therapeutic Resistance.

Lung adenocarcinoma (LUAD) exhibits metabolic flexibility that transcends the classical interpretation of the Warburg effect. This review proposes the concept of "adaptive mitochondrial specialization (AMS)", an integrative framework in which mitochondria undergo coordinated, context-dependent remodeling of bioenergetic metabolism, redox homeostasis,...

🗓️ 2026-10-27
Read MoreAdaptive Mitochondrial Specialization in Lung Adenocarcinoma: Redox Homeostasis, Hypoxia Adaptation, and Therapeutic Resistance.

Sulforaphane as a Therapeutic Target for Sarcopenia in Type 2 Diabetes: Mechanistic Insights and Translational Evidence.

Sulforaphane, a bioactive isothiocyanate abundant in cruciferous vegetables, has emerged as a potential multi-target therapeutic agent capable of mitigating these pathological processes. Here, using evidence from preclinical and clinical literature, we review the mechanistic and translational evidence linking sulforaphane with...

🗓️ 2026-10-27
Read MoreSulforaphane as a Therapeutic Target for Sarcopenia in Type 2 Diabetes: Mechanistic Insights and Translational Evidence.

Aging of Skeletal Muscle: From Molecular Mechanisms to Therapeutic Interventions.

Skeletal muscle aging is a major cause of frailty, metabolic dysfunction, and loss of independence in later life, yet it cannot be explained by muscle mass loss alone. Recent single-cell, multi-omics, and translational studies show that aged muscle is shaped...

🗓️ 2026-09-22
Read MoreAging of Skeletal Muscle: From Molecular Mechanisms to Therapeutic Interventions.

UA-30 mitigates systemic aging and motor decline by inhibiting RalA signaling in naturally aged mice.

Aging, characterized by progressive physiological decline and systemic dysfunction, represents a major risk factor for age-related diseases such as sarcopenia, which involves fibrosis that disrupts muscle regeneration and function. Effective therapeutic strategies remain limited. Here we report UA-30, a novel...

🗓️ 2026-09-16
📰 Publication: Journal Of Experimental Medicine
Read MoreUA-30 mitigates systemic aging and motor decline by inhibiting RalA signaling in naturally aged mice.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!